ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO135

Association of Presence of Diabetes with Failure to Complete Remission of Idiopathic Membranous Nephropathy

Session Information

Category: Glomerular

  • 1005 Clinical Glomerular Disorders

Authors

  • Xie, Huaiya, Peking Union Medical College Hospital, Beijing, China
  • Wu, Zhen, Beijing Friendship Hospital, Capital Medical University, Beijing, China
  • Zhang, Xin, Peking University First Hospital, Beijing, China
  • Wen, Yubing, Peking Union Medical College Hospital, Beijing, China
  • Cai, Jianfang, Peking Union Medical College Hospital, Beijing, China
  • Li, Hang, Peking Union Medical College Hospital, Beijing, China
  • Li, Xuemei, Peking Union Medical College Hospital, Beijing, China
  • Li, Xuewang, Peking Union Medical College Hospital, Beijing, China
Background

This study aimed to assess whether the presence of diabetes will influence renal outcomes in patients with idiopathic membranous nephropathy (IMN).

Methods

In this retrospective study, a total of 875 patients with pathology-proved IMN were consecutively enrolled. Among them, 101 were diagnosed as type 2 diabetes mellitus (T2DM) prior to their diagnosis of IMN. Data on age, sex, body mass index (BMI), presence of hypertension and diabetes mellitus, laboratory tests, and therapeutic regimens were retrospectively retrieved from medical record. Complete remission (CR) was defined as urinary protein excretion<0.3g/d with stable estimated glomerular filtration (eGFR). COX regression was used to analyze risks of failure to CR and renal function deterioration associated with the presence of T2DM.

Results

A total of 810 patients were followed at least once with a median follow-up of 23.6 (IQR 9.9-42) months, of whom 292 achieved CR and 95 developed a 30% decline in eGFR. Presence of T2DM was associated with failure to reach CR of IMN (HR=0.53, 95% CI 0.37-0.77, P =0.001), independently of age, sex, hypertension, therapeutic regimen, serum albumin, proteinuria, and baseline eGFR. The association remained statistically significant when we further excluded 103 patients with corticosteroid-induced diabetes(HR=0.49, 95% CI 0.34-0.71,P <0.001), or restricted the analyses in patients with nephrotic syndrome(HR=0.46,95% CI 0.28-0.67,P =0.002) or in those using calcineurin inhibitors(HR=0.58,95% CI 0.37-0.91, P =0.017). However, patients with and without T2DM did not differ in developing a 30% decline in eGFR, adjusting for age, sex, BMI, state of smoking, hypertension, therapeutic regimen, serum albumin, proteinuria, and baseline eGFR(HR=0.67,95% CI 0.39-1.16,P =0.156).

Conclusion

Presence of T2DM may be independently associated with failure to remission but not eGFR decline in IMN patients.